triamcinolone acetonide · Bausch And Lomb Inc · NDA 211950
Xipere
Earliest generic entry, as listed
16 Apr 2040
Blocked by patent: US 12419833.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12419833 | product, use U-3234 | 16 Apr 2040 |
| US 9937075 | product | 2 May 2034 |
| US 9636332 | use U-3234 | 8 Nov 2033 |
| US 8636713 | use U-3234 | 2 May 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 211950 · 001 · RLD | suspension, injection | 40MG/ML | 16 Apr 2040 |